Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease

Amino Acids

Volumn 23, Issue 1-3, 2002, Pages 57-63

  Kostrzewa, R M ^a   Kostrzewa, J P ^a   Brus, R ^b  

^a East Tennessee State University   (United States)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

L DOPA Parkinson's disease; Reactive oxygen species

Indexed keywords

ANTIOXIDANT; BENSERAZIDE; CARBIDOPA; CATECHOL; DESIPRAMINE; DNA; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE; GUANINE; LEVODOPA; OXIDOPAMINE; PROTEIN; QUINONE DERIVATIVE; REACTIVE OXYGEN METABOLITE; THIOL DERIVATIVE;

AUTOOXIDATION; CHEMICAL REACTION; CONFERENCE PAPER; CROSS LINKING; CYTOTOXICITY; DEGENERATIVE DISEASE; DISEASE COURSE; EPIDEMIOLOGICAL DATA; HUMAN; HYDROXYLATION; IN VITRO STUDY; IN VIVO STUDY; LIPID PEROXIDATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL;

ANIMALS; ANTIPARKINSON AGENTS; CATECHOLS; DOPAMINE; HUMANS; LEVODOPA; NEURODEGENERATIVE DISEASES; NEURONS; NEUROPROTECTIVE AGENTS; NEUROTOXINS; OXIDATIVE STRESS; PARKINSON DISEASE; REACTIVE OXYGEN SPECIES;

EID: 0036391982     PISSN: 09394451     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00726-001-0110-x     Document Type: Conference Paper

References (92)

1. Anglande P, Vyas S, Javoy-Agid F (1997) Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol 12: 25-31
2. Baez S, Linderson Y, Segura-Aguilar J (1995) Superoxide dismutase and catalase enhance autoxidation during one-electron reduction of aminochrome by NADPH-cytochrome P-450 reductase. Biochem Mol Med 54: 12-18
3. Ben-Shachar D, Zuk R, Glinka Y (1995) Dopamine neurotoxicity: Inhibition of mitochondrial respiration. J Neurochem 64: 718-723
4. Berlett BS, Stadman (1997) Protein oxidation in aging, disease and oxidative stress. J Biol Chem 272: 20313-20316
5. Berman SB, Hastings TG (1999) Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: Implications for Parkinson's disease. J Neurochem 73: 1127-1137
6. Camp DM, Loeffler DA, LeWitt PA (2000) L-DOPA does not enhance hydroxyl radical formation in the nigrostriatal dopamine system of rats with a unilateral 6-hydroxydopamine lesion. J Neurochem 74: 1229-1240
7. Chen CS, Chao HT, Pan RL, Wei YH (1997) Hydroxyl radical-induced decline in motility and increase in lipid peroxidation and DNA modification in human sperm. Biochem Mol Biol Intl 43: 291-303
8. Chen JW, Zang L, Lian X, Hwang F (1992) Effect of hydroxyl radical on Na(+)-K(+)-ATPase activity on the brain microsomal membranes. Cell Biol Intl Rep 16: 927-936
9. Colado MI, O'Shea E, Granados R, Esteban B, Martin AB, Green AR (1999) Studies on the role of dopamine in the degeneration of 5-HT nerve endings in the brain of Dark Agouti rats following MDMA or "ecstasy" administration. Br J Pharmacol 126: 911-924
10. Datla KP, Blunt SB, Dexter DT (2001) Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions. Mov Disord 16: 424-434
11. de la Monte SM, Sohn YK, Ganju N, Wands JR (1998) p53- and CD95-associated apoptosis in neurodegenerative diseases. Lab Invest 78: 401-411
12. Ebadi M, Govitrapong P, Sharma S, Muralikrishnan D, Shavali S, Pellett L, Schafer R, Albano C, Eken J (2001) Ubiquinone (coenzyme q(10)) and mitochondria in oxidative stress of parkinson's disease. Biol Signals Recept 10: 224-253
13. Fenton HJH (1894) Oxidation of tartaric acid in the presence of iron. J Chem Soc 65: 899-910
14. Filloux F, Townsend JJ (1993) Pre- and post-synaptic neurotoxic effects of dopamine demonstrated by intrastriatal injection. Exp Neurol 119: 79-88
15. Foppoli C, Coccia R, Cini C, Rosei MA (1997) Catecholamine oxidation by xanthine oxidase. Biochim Biophys Acta 1334: 200-206
16. Fornstedt B, Brun A, Rosengren E, Carlsson A (1989) The apparent autoxidation rate of catechols in dopamine-rich regions of human brain increases with the degree of depigmentation of substantia nigra. J Neural Transm [-PD Sect.] 1: 279-295
17. Fornstedt B, Pileblad E, Carlsson A (1990) In vivo autoxidation of dopamine in guinea pig striatum increases with age. J Neurochem 55: 655-659
18. Graham DG (1978) Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 14: 633-643
19. Gwinn-Hardy K, Evidente VG, Waters C, Muenter MD, Hardy J (1999) L-dopa slows the progression of familial parkinsonism. Lancet 353: 1850-1851
20. 2 by iron salts. Proc Royal Soc London (Biol) 147: 332-351
21. Han X, Liehr JG (1994a) DNA single strand breaks in kidneys of Syrian hamsters treated with steroidal estrogens. Hormone-induced free radical damage preceding renal malignancy. Carcinogenesis 15: 997-1000
22. Han X, Liehr JG (1994b) 8-Hydroxylation of guanine bases in kidney and liver DNA of hamsters treated with estradiol: Role of free radicals in estrogen-induced carcinogenesis. Cancer Res 54: 5515-5517
23. Han X, Liehr JG (1995) Microsome-mediated 8-hydroxylation of guanine bases of DNA by steroid estrogens: Correlation of DNA damage by free radicals with metabolic activation to quinones. Carcinogenesis 16: 2571-2574
24. Hastings TG (1995) Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J Neurochem 64: 919-924
25. Hastings TG, Zigmond MJ (1994) Identification of catechol-protein conjugates in neostriatal slices incubated with [3H]dopamine: impact of ascorbic acid and glutathione. J Neurochem 63: 1126-1132
26. Hastings TG, Lewis DA, Zigmond MJ (1996) Role of oxidation in the neurotoxic effects of intrastriatal DA injections. Proc Natl Acad Sci USA 93: 1956-1961
27. Hawley MD, Tatawawadi SV, Piekarski S, Adams RN (1967) Electrochemical studies of the oxidation pathways of catecholamines. J Am Chem Soc 89: 447-450
28. Heacock RA (1959) The chemistry of adrenochrome and related compounds. Chem Rev 59: 181-327
29. Hoyt KR, Reynolds IJ, Hastings TG (1997) Mechanisms of dopamine-induced cell death in cultured rat forebrainneurons: interactions with and differences from glutamate-induced cell death. Exp Neurol 143: 269-281
30. Hunot S, Brugg B, Ricard D, Michel PP, Muriel MP, Ruberg M, Faucheux BA, Agid Y, Hirsch EC (1997) Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with Parkinson's disease. Proc Natl Acad Sci USA 94: 7531-7536
31. Ilic TV, Jovanovic M, Jovicic A, Tomovic M (1999) Oxidative stress indicators are elevated in de novo Parkinson's disease patients. Funct Neurol 14: 141-147
32. Ito S, Fujita K (1982) Conjugation of dopa and 5-S-cysteinyldopa with cysteine mediated by superoxide radical. Biochem Pharmacol 31: 2887-2889
33. Ito S, Kato T, Fujita K (1988) Covalent binding of catechols to proteins through the sulfhydryl group. Biochem Pharmacol 37: 1707-1710
34. Jellinger K, Paulus W, Grundke-Iqbal I, Riederer P, Youdim MB (1990) Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J Neural Transm Park Dis Dement Sect 2: 327-340
35. Jenner PG, Brin MF (1998) Levodopa neurotoxicity: experimental studies versus clinical relevance. Neurology 50[Suppl 6], S39-S43; discussion S44-S48
36. Kato T, Ito S, Fujita K (1986) Tyrosinase-catalyzed binding of 3,4-dihydroxyphenylalanine with proteins through the sulfhydryl group. Biochim Biophys Acta 881: 415-421
37. Koeppen AH (1995) The history of iron in the brain. J Neurol Sci 134[Suppl]: 1-9
38. Korytowski W, Sarna T, Kalyanaraman B, Sealy RC (1987) Tyrosinase-catalyzed oxidation of dopa and related catecholamines: a kinetic electron spin resonance investigation using spin-stabilization and spin label oximetry. Biochim Biophys Acta 924: 383-392
39. Kostrzewa RM (2000) Review on apoptosis vs. necrosis of substantia nigra pars compacta in Parkinson's disease. Neurotoxicity Res 2: 239-250
40. Kostrzewa RM, Kostrzewa JP, Brus R (2000) Dopaminergic denervation enhances susceptibility to hydroxyl radicals in rat neostriatum. Amino Acids 19: 183-199
41. Kristal BS, Conway AD, Brown AM, Jain JC, Ulluci PA, Li SW, Burke WJ (2001) Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria. Free Radic Biol Med 30: 924-931
42. LaVoie MJ, Hastings TG (1997) Peroxynitrite potentiates the oxidation of dopamine in vitro: implications for MPTP- and methamphetamine-induced toxicity. Soc Neurosci Abstr 23: 1371
43. LaVoie MJ, Hastings TG (1999) Peroxynitrite and nitrite induce oxidation of dopamine: implications for nitric oxide in dopaminergic cell loss. J Neurochem 73: 2546-2554
44. Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E, Harta G, Brownstein MJ, Jonnalagada S, Chemova T, Dehejia A, Lavedan C, Gasser T, Steinbach PJ, Wilkinson KD, Polmeropoulos MH (1998) The ubiquitin pathway in Parkinson's disease. Nature 395: 451-452
45. Liehr JG, Ulubelen AA, Strobel HW (1986) Cytochrome P450-mediated redox cycling of estrogens. J Biol Chem 261: 16865-16870
46. Liu TZ, Lin TF, Chiu DT, Tsai KJ, Stern A (1997) Palladium or platinum exacerbates hydroxyl radical mediated DNA damage. Free Radic Biol Med 23: 155-161
47. Luo Y, Umegaki H, Wang X, Abe R, Szatmary I (1998) Dopamine induces apoptosis through an oxidation-involved SAPK/JNK activation pathway. J Biol Chem 273: 3756-3764
48. Markides C, Liehr JG (1998) Concentration-dependence of pro-oxidant and antioxidant properties of catechol estrogens. Arch Biochem Biophys 360: 105-112
49. Mattammal MB, Strong R, Laksmi VM, Chung HD, Stephanson AH (1995) Prostaglandin H synthase-mediated metabolism of dopamine: implications for Parkinson's disease. J Neurochem 64: 1645-1654
50. McLaughlin BA, Nelson D, Erecinska M, Chesselet (1998) Toxicity of dopamine to striatal neurons in vitro and potentiation of cell death by a mitochondrial inhibitor. J Neurochem 70: 2406-2415
51. Melamed E, Offen D, Shirvan A, Djaldetti R, Barzilai A, Ziv I (1998) Levodopa toxicity and apoptosis. Ann Neurol 44: S149-154
52. Michel PP, Hefti F (1990) Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J Neurosci Res 26: 428-435
53. Mischel RE, Kim YS, Sheldom RA, Ferriero DM (1997) Hydrogen peroxide is selectively toxic to immature murine neurons in vitro. Neurosci Lett 231: 17-20
54. 3+. Chem Biol Interact 85: 243-254
55. Moichizuki H, Goto K, Mori H, Mizuno Y (1996) Histology detection of apoptosis in Parkinson's disease. J Neurol Sci 137: 120-123
56. Monks TJ, Hanzlik RP, Cohen GM, Ross D, Graham DG (1992) Quinone chemistry and toxicity. Toxicol Appl Pharmacol 112: 2-16
57. Montine TJ, Farris DB, Graham DG (1995) Covalent crosslinking of neurofilament proteins by oxidized catechols as a potential mechanism of Lewy body formation. J Neuropathol Exp Neurol 54: 311-319
58. Morikawa N, Nakagawa-Hattori Y, Mizuno Y (1996) Effect of dopamine, dimethoxyphenylethylamine, papaverine, and related compounds on mitochondrial respiration and Complex I activity. J Neurochem 66: 1174-1181
59. Morris CM, Edwardson JA (1994) Iron histochemistry of the substantia nigra in Parkinson's disease. Neurodegeneration 3: 277-282
60. Murer MG, Dziewczapolski G, Menalled LB, Garcia MC, Agid Y, Gershanik O, Raisman-Vozari R (1998) Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 43: 561-575
61. Nappi AJ, Vass E, Prota G, Memoli S (1995) The effect of hydroxyl radical attack on dopa, dopamine, 6-hydroxydopa, and 6-hydroxydopamine. Pigment Cell Res 8: 283-293
62. Obata T, Yamanaka Y (1996) Protective effect of carbidopa on hydroxyl radical generation in the rat striatum by dopamine. Neurosci Lett 221: 13-16
63. Offen D, Ziv I, Gorodin A, Barzilai A, Malik Z, Melamed E (1995) Dopamine-induced programmed cell death in mouse thymocytes. Biochim Biophys Acta 1268: 171-177
64. Offen D, Ziv I, Barzilai A, Gorodin S, Glater E, Hochman A, Melamed E (1997) Dopamine-melanin induces apoptosis in PC12 cells: possible implications for the etiology of Parkinson's disease. Neurochem Int 31: 207-216
65. Perry TL, Godin DV, Hansen S (1982) Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 33: 305-310
66. Prinsze C, Dubbelman TM, Van Stevenick J (1990) Protein damage, induced by small amounts of photodynamically generated singlet oxygen or hydroxyl radicals. Biochim Biophys Acta 1038: 152-157
67. Przedborski S, Jackson-Lewis V, Muthane U, Jiang H, Ferreira M, Naini AB, Fahn S (1993) Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity. Ann Neurol 34: 715-723
68. Rosei MA, Blarzino C, Foppoli C, Mosca L, Coccia R (1994) Lipoxygenase-catalyzed oxidation of catecholamines. Biochem Biophys Res Commun 200: 344-350
69. Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, Youdim MB (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52: 515-520
70. Sanchez-Ramos JR, Overvik E, Ames BN (1994) A marker of oxyradical-mediated DNA damage (8-hydroxy-2-deoxyguanosine is increased in nigrostriatum of Parkinson's disease brain. Neurodegeneration 3: 197-204
71. 3 and oxidation of dopamine to aminochrome. Biochem Mol Med 58: 122-129
72. Segura-Aguilar J, Metodiewa D, Welch C (1998) Metabolic activation of dopamine o-quinones to o-semiquinones by NADPH cytochrome P450 reductase may play an important role in oxidative stress and apoptotic effects. Biochim Biophys Acta 381: 1-6
73. Senoh S, Creveling CR, Udenfriend S, Witkop B (1959) Chemical, enzymatic and metabolic studies on the mechanism of oxidation of dopamine. J Am Chem Soc 81: 6231-6240
74. Shen XM, Xia B, Wrona MZ, Dryhurst G (1996) Synthesis, redox properties, in vivo formation, and neurobehavioral effects of N-acetylcysteinyl conjugates of dopamine: possible metabolites of relevance to Parkinson's disease. Chem Res Toxicol 9: 1117-1126
75. Shirvan A, Ziv I, Barzilai A, Djaldeti R, Zilkh-Falb R, Michlin T, Melamed E (1997) Induction of mitosis-related genes during dopamine-triggered apoptosis in sympathetic neurons. J Neural Transm [Suppl 50]: 67-78
76. Shoffner JM, Watts RL, Juncos JL, Torroni A, Wallace DC (1992) Mitochondrial oxidative phosphorylation defects in Parkinson's disease. Ann Neurol 32: 226-227
77. Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P, Marsden CD (1994) Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36: 333-334
78. Smith TS, Parker WD Jr, Bennett JP Jr (1994) L-Dopa increases nigral production of hydroxyl radicals in vivo: potential L-dopa toxicity? Neuroreport 5: 1009-1011
79. Spencer JPE, Jenner P, Halliwell B (1995) Superoxide-dependent depletion of reduced glutathione by L-dopa and dopamine: Relevance to Parkinson's disease. Neuroreport 6: 1480-1484
80. Spenser JP, Jenner A, Butler J, Aruoma OI, Dexter DT, Jenner P, Halliwell B (1996) Evaluation of the pro-oxidant and antioxidant actions of L-DOPA and dopamine in vitro: implications for Parkinson's disease. Free Radic Res 24: 95-105
81. Stadtman ER (1992) Protein oxidation and aging. Science 257: 1220-1224
82. Takashima H, Tsujihata M, Kishikawa M, Freed WJ (1999) Bromocriptine protects dopaminergic neurons from levodopa-induced toxicity by stimulating D(2)receptors. Exp Neurol 159: 98-104
83. Tatton NA, MacLean-Fraser A, Tatton WG, Perl DP, Olanow CW (1998) A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease. Ann Neurol 44: S142-S148
84. Walkinshaw G, Waters, CM (1995) Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA: Implications for the treatment of Parkinson's disease. Induction of apoptotis in catecholaminergic PC12 cells by L-DOPA. J Clin Invest 95: 2458-2464
85. Tran PB, Miller RJ (1999) Aggregates in neurodegenerative disease: crowds and power? Trends Neurosci 22: 194-197
86. Wang MY, Liehr JG (1995) Induction by estrogens of lipid peroxidation and lipid peroxide-derived malonaldehyde-DNA adducts in male Syrian hamsters: role of lipid peroxidation in estrogen induced kidney carcinogenesis. Carcinogenesis 16: 1941-1945
87. Wick MM (1979) Levodopa and dopamine analogs: Melanin precursors as antitumor agents in experimental human and murine leukemia. Cancer Treat Rep 63: 991-997
88. Wick MM (1980) Levodopa and dopamine analogs as DNA polymerase inhibitors and antitumor agents in human melanoma. Cancer Res 40: 1414-1418
89. Wick MM (1989) Levodopa/dopamine analogs as inhibitors of DNA synthesis in human melanoma cells. J Invest Dermatol 92: S329-331
90. Wick MM, Byers L, Frei E (1977) L-dopa: Selective toxicity for melanoma cells in vitro. Science 197: 468-469
91. Youdim MBH, Ben-Shachar D, Riederer P (1993) The role of iron in etiopathology of Parkinson's disease. Mov Disord 8: 1-12
92. Zhang J, Price JO, Graham DG, Montine TJ (1998) Secondary excitotoxicity contributes to dopamine-induced apoptosis of dopaminergic neuronal cultures. Biochem Biophys Res Commun 248: 812-816